Introduction

Many of nowadays most threatening diseases are caused by mutations, epi mutations or other changes in the genome. Although medical research was always supplied by innovations in biological research and especially by the field of genetics, which developed rapidly during the last decades, there are still many diseases that cannot be cured or even treated adequately. Recently, the CRISPR/Cas9 technology raised hope of the scientific community to treat genetic disorders. This technique has dramatically simplified the way genomes can be manipulated. However, there are still many challenges to be surpassed. Cas9 and related endonucleases are enzymes, which are able to induce double strand breaks in the genome. Importantly, they only cut specific sequences to which they are guided by a so called guideRNA (gRNA). A gRNA consists of a 3' scaffold, which is obligatory for the binding of the Cas9 enzyme, a protospacer sequence, and 20 nucleotides at the 5'-end that are complementary to the target DNA. Once the Cas9 endonuclease binds to the DNA, it cleaves three nucleotides upstream of the protospacer 3'-end. This system allows to target virtually any position in any genome. However, there is one major restriction in the applicability of this system. Only sequences can be targeted that carry a specific recognition motif directly downstream of the spacer, the protospacer adjacent motif (PAM). In case of Cas9, the consensus PAM is NGG Jinek2012. The past few years, much effort has been put into the development of the CRISPR/Cas9 technique. In order to create even more sophisticated systems, many attempts have been made to modify the CRISPR-associated (Cas) endonucleases, for example the development of a catalytically inactive dCas9 RN141 or nickases Mali2013x. Attempts to change endonuclease activity by directed evolution have already been made JM_5Gao2017. As add on to our PACE toolbox, we decided to show that in vivo directed evolution of endonucleases is possible as well. This approach would overcome the limitations of the evolution based on rationalities and would offer new tools for the genome engineering research area.

Figue 1: Principle of PACE for the Evolution of Cas9

The production of phages is linked to the fitness of Cas9 via the phusion to rpoZ When the gRNA targets the fusion protein to a sequence upstream of the promoter, the rpoZ is able to recruit the transcription machinery and therefore activates genVI expression and subsequently phage production. When the PAM upstream of the spacer is altered, Cas9 cannot bind anymore and the expression stops. In context of PACE the nuclease mutates. Mutants of Cas9 with that can bind to the new PAM, activate ProteinVI production. This provides a fitness benefit. With the generation of randomized PAM libraries, the overall PAM specificity can be decreased, which is of great interest for many gene editing applications

The Idea

To prove our hypothesis, we planned a circuit for the directed evolution of PAM specificity of Cas9 (Fig. 1). The main challenge was to link transcription activation to the binding of Cas9. We chose a system, which contains a dCas9 fused to a RNA polymerase Ω subunit (rpoZ) BIKARDETAL..2013. The rpoZ is able to recruit the transcription machinery to a poromoter and therefore activate gene expression. In our scenario, the nuclease targets a region upstream of a minimal promoter. In case the dCas9 is able to bind the DNA, the fused rpoZ activates gene expressio expreession. The J23117 promoter from the registry was chosen for activation BIKARDETAL..2013. It stands our through its low background activity and can be activated by the factor of 23 when rpoZ binds. Upstream of the promoter sequence, a spacer with a wildtype NGG PAM, that was previously used to target RFP was placed QIETAL..2013. If the Cas9 is able to bind to the spacer, transcription is activated. By changing the PAM sequence or generating PAM libraries, it is possible to induce a selection pressure on the randomly mutating protein. As a result, proteins with a weaker PAM specificity evolve, which can be used, no matter if the NGG motif is present exactly at the desired position. Of course, this circuit was designed according to our cloning standard by Gibson assembly.

Phage Based in vivo Eolution with GeneVI

One of the major challenges in the context of transcription activation with help of the rpoZ is leaky expression. This is a setious problem for PACE, because if geneIII is expressed prior to phage infection leads to infection the bactirial cell turns resistant RN44. Fortunately, it was shown that geneVI can be used for phage propagation in the context of directed evolution as well. In contrast to the commonly used geneIII, it has the advantage that leaky geneVI expression has no effect on the infectivity of E. coli by phages BRODELETAL..2016. As a consequence, we decided to adapt this approach and towork with geneVI instead of geneIII. All parts, which were necessary for the assembly of Accessory Plasmids were generated by PCR with the respective homology regions in the extensions. Subsequently, they were assembled by Gibson assembly (Fig.:2). All APs carry a bicistronic operon for the expression of geneIII and luxAB as luminescent reporter downstream of the promoter, described above. An expression cassette with the required gRNA under the control of a constitutive promoter is located on the same plasmid. APs varying in the copy number of their origins of replication and the strength of the RBS upstream of geneVI were cloned. To evolve the PAM specificity, we generated PAM libraries with four randomized nucleotides next to the spacer sequence. In order to do so, the whole plasmid was PCR amplified with the four PAM nucleotides as primer extensions. Subsequently, the plasmid was reassembled by Golden Gate assembly. To avoid that nucleotides, that pair with the original PAM are preferred and overrepresented in the library, a BbsI site was inserted next to the PAM. Prior to the PCR, the plasmid was digested with the enzyme, resulting in a linear fragment. The four nucleotides were loceated in overhangs, in the strand, to which the primer cannot bind. Plasmids that were cloned for the evolution of PAM specificity, the plasmid names, and the functional parts they consist of are shown in (Tab.: 1).

Figure 2: Design of the Accessory Plasmids for the Evolution of Cas9

The AP consists of five subparts that are devided by homology regions for Gibson assembly (numbers). It carries an expression cassette for the transcription of a gRNA (between 1 and 5). GeneVI (2-3) is under control of a that can be activated by the Cas9-rpoZ in context with the respective gRNA. luxAB accounts as a reporter for fluorescent readout of geneIII activation (3-4). The whole plasmid can be produced with different origins of replication (4-5) to modulate the copy number and by exchanging the geneVI part with the RBS.

Our Accessory Plasmids for PACE of Endonucleases The different accessory plasmids that were cloned in the context of this project are shown. The constructs differ in their copy number and the strength of their RBSs.

Puri-ID	AP	Regulatory Sequence	RBS of geneIV	Origin of replication	gRNA cassette	PAM
821	AP_Cas9_pSC101_NNNN_SD8_GVI	minimal promoter downstram of the dCas9 target sequence	SD8	pSC101	gRNA expression cassette	NNNN
822	AP_Cas9_pSC101_NNNN_sd8_GVI	minimal promoter downstram of the dCas9 target sequence	sd8	pSC101	gRNA expression cassette	NNNN
823	AP_Cas9_pSC101_NNNN_sd6_GVI	minimal promoter downstram of the dCas9 target sequence	sd6	pSC101	gRNA expression cassette	NNNN
824	AP_Cas9_pSC101_NNNN_SD4_GVI	minimal promoter downstram of the dCas9 target sequence	sd4	pSC101	gRNA expression cassette	NNNN
825	AP_Cas9_pSC101_NNNN_sd2_GVI	minimal promoter downstram of the dCas9 target sequence	sd2	pSC101	gRNA expression cassette	NNNN
826	AP_Cas9_pSC101_NGAN_SD8_GVI	minimal promoter downstram of the dCas9 target sequence	SD8	pSC101	gRNA expression cassette	NGAN
829	AP_Cas9_pSC101_NGAN_SD4_GVI	minimal promoter downstram of the dCas9 target sequence	sd4	pSC101	gRNA expression cassette	NGAN
830	AP_Cas9_pSC101_NGAN_sd2_GVI	minimal promoter downstram of the dCas9 target sequence	sd2	pSC101	gRNA expression cassette	NGAN